Volume 15, Issue 4 (September 2023 2023)                   Iranian Journal of Blood and Cancer 2023, 15(4): 272-292 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Wajahat S. Role of microorganisms in the developmental, prognostic, and therapeutics of gastric cancer. Iranian Journal of Blood and Cancer 2023; 15 (4) :272-292
URL: http://ijbc.ir/article-1-1437-en.html
Department of Biosciences, Mohammad Ali Jinnah University, Karachi, Pakistan , s.sadaf.wajahat@gmail.com
Abstract:   (756 Views)
Gastric cancer (GC) is the most frequent destructive polyp allied to the GIT. It is reported as the foremost oncological complication with a prevalence ranks fifth and mortality ranks fourth worldwide with a survival rate of <25% in five years. In GC, men were observed as 2-3 times more susceptible to incidence and mortality than women. The GC patients experienced a burden of symptoms with multiple co-occurring symptoms including pain, weight loss, depression, fatigue, dysphagia, nausea, vomiting, etc. The risk factors of GC include infection of H. pylori, smoking, obesity, hereditary, high salt, radiation, and the frequent use of medications, etc. The role of genes, long-coding RNAs, metabolomics, machine learning, plant extracts, and nanoparticles has been studied for the progression, diagnosis, and treatment of GC. Due to the progressive stage diagnosis and lack of competent therapy, an imperative requirement is the identification of sensitive and accurate biomarkers towards the initial prognosis and the development of innovative therapeutic approaches. Microorganisms execute a momentous role in human health by contributing to immune system development and accomplishing an extensive range of metabolic functions. The disturbance in the stability of the microbes may stimulate various diseases including cancer. This review focuses on the role of microorganisms in the development, prognosis, and therapy of GC.
Full-Text [PDF 7319 kb]   (239 Downloads)    
: Review Article | Subject: Gastroentrology
Received: 2023/07/6 | Accepted: 2023/09/18 | Published: 2023/09/27

1. Chen S, Wei Y, Liu H, Gong Y, Zhou Y, Yang H, Tang L. Analysis of Collagen type X alpha 1 (COL10A1) expression and prognostic significance in gastric cancer based on bioinformatics. Bioengineered. 2021;12(1):127-37. [DOI:10.1080/21655979.2020.1864912]
2. Li H, Wang J, Wang W, Wang H, Lv JQ. Effect of miR-26a-5p on gastric cancer cell proliferation, migration, and invasion by targeting COL10A1. European Review for Medical and & Pharmacological Sciences. 2020; 24(3):1186-94.
3. Sun H, Wang Y, Wang S, Xie Y, Sun K, Li S, Cui W, Wang K. The involvement of collagen family genes in tumor enlargement of gastric cancer. Scientific Reports 2023; 13(1):100. [DOI:10.1038/s41598-022-25061-0]
4. Zhuo W, Liu Y, Li S, Guo D, Sun Q, Jin J, Rao X, Li M, Sun M, Jiang M, Xu Y, Teng L, Jin Y, Si J, Liu W, Kang Y, Zhou T. Long Noncoding RNA GMAN, Up-regulated in Gastric Cancer Tissues, Is Associated With Metastasis in Patients and Promotes Translation of Ephrin A1 by Competitively Binding GMAN-AS. Gastroenterology. 2019; 156(3):676-91. [DOI:10.1053/j.gastro.2018.10.054]
5. Liang M, Huang G, Liu Z, Wang Q, Yu Z, Liu Z, Lin H, Li M, Zhou X, Zheng Y. Elevated levels of hsa_circ_006100 in gastric cancer promote cell growth and metastasis via miR‐195/GPRC5A signalling. Cell Proliferation. 2019;52(5):12661. [DOI:10.1111/cpr.12661]
6. Global Cancer Observatory: International Agency for Research on Cancer: World Health Organization, 2020. Cancer Fact Sheet. https://gco.iarc.fr/today/data/factsheets/cancers/7-Stomach-fact-sheet.pdf (accessed 8 January 2023).
7. Cheng XJ, Lin JC, Tu SP. Etiology and prevention of gastric cancer. Gastrointestinal tumours 2016;3(1):25-36. [DOI:10.1159/000443995]
8. Hwang M-A, Won M, Im J-Y, Kang M-J, Kweon D-H, Kim B-K. TNF− α Secreted from Macrophages Increases the Expression of Prometastatic Integrin αV in Gastric Cancer. International Journal of Molecular Sciences. 2023; 24(1):376. [DOI:10.3390/ijms24010376]
9. Afzal A, Qayyum MA, Shah MH. Comparative assessment of trace elements in the blood of gastric cancer patients and healthy subjects. Biointerface Research in Applied Chemistry. 2020;11:10824-43. [DOI:10.33263/BRIAC113.1082410843]
10. Shabbir A, Qureshi MA, Khalid AB, Mirza T, Shaikh A, Hasan SM. Gastric adenocarcinoma expressing human epidermal growth factor receptor in South Asian population. Saudi Journal of Gastroenterology. 2018;24(5):289-93. [DOI:10.4103/sjg.SJG_23_18]
11. Yousaf A, Tasneem N, Mustafa A, Fatima R, Nabia N, Khan RA, Abdulbasit H, Abubakar M, Asadullah A, Rizwan R, Baqa-ur-Rehman B. Gastric cancer associated risk factors and prevalence in Pakistan. ASEAN Journal of Science and Engineering. 2021;1(2):73-8. [DOI:10.17509/ajse.v1i2.41124]
12. Zhang Z, Peng L, Yang W, Li B, Hua Y, Luo S. PHF5A facilitates the development and progression of gastric cancer through SKP2-mediated stabilization of FOS. Journal of Translational Medicine. 2023;21(1):1-4. [DOI:10.1186/s12967-022-03821-w]
13. Pham QT, Taniyama D, Akabane S, Takashima T, Maruyama R, Sekino Y, Sentani K, Yasui W, Oue N. Essential Roles of TDO2 in Gastric Cancer: TDO2 Is Associated with Cancer Progression, Patient Survival, PD-L1 Expression, and Cancer Stem Cells. Pathology. 2023;90(1):44-55. [DOI:10.1159/000523750]
14. Ni T, Chu Z, Tao L, Zhao Y, Zhu M, Luo Y, Sunagawa M, Wang H, Liu Y. PTBP1 drives c-Myc-dependent gastric cancer progression and stemness. British Journal of Cancer. 2023;128(6):1005-18. [DOI:10.1038/s41416-022-02118-5]
15. Li A, Guo Y, Yin Z, Liu X, Xie G. MTA2 is one of 14 Transcription factors predicting recurrence free survival in gastric cancer and promotes cancer progression by targeting MCM5. Journal of Cancer. 2023;14(2):262-74. [DOI:10.7150/jca.77402]
16. An L, Liu Y. ZNF460 mediates epithelial-mesenchymal transition to promote gastric cancer progression by transactivating APOC1 expression. Experimental Cell Research. 2023;422(2):113452. [DOI:10.1016/j.yexcr.2022.113452]
17. Ding K, Zhang F, Qi G, Lin M, Chen M, Chen Y, Zheng J, Zhou F. ZFP36L1 Promotes gastric cancer progression via regulating JNK and p38 MAPK signaling pathways. Recent Patents on Anti-Cancer Drug Discovery. 2023;18(1):80-91. [DOI:10.2174/1574892817666220524102403]
18. Lin X, Li G, Yan X, Fu W, Ruan J, Ding H, Yu H, Chen X, Lan L, Dai Y, Pan K. Long non-coding RNA BC002811 Promotes Gastric Cancer Metastasis by Regulating SOX2 Binding to the PTEN Promoter. International Journal of Biological Sciences. 2023;19(3):967-80. [DOI:10.7150/ijbs.76407]
19. Wang S, Qiao C, Li J, Liu S, Li P. LncRNA CASC19 promotes gastric cancer progression through preventing CREB1 protein ubiquitin/proteasome-dependent degradation. Carcinogenesis. 2023;44(3): 209-20. [DOI:10.1093/carcin/bgad001]
20. Dong C, Luan F, Tian W, Duan K, Chen T, Ren J, Li W, Li D, Zhi Q, Zhou J. Identification and validation of crucial lnc-TRIM28-14 and hub genes promoting gastric cancer peritoneal metastasis. BMC Cancer. 2023; 23(1):76. [DOI:10.1186/s12885-023-10544-8]
21. Mochalski P, Leja M, Ślefarska-Wolak D, Mezmale L, Patsko V, Ager C, Królicka A, Mayhew CA, Shani G, Haick H. Identification of Key Volatile Organic Compounds Released by Gastric Tissues as Potential Non-Invasive Biomarkers for Gastric Cancer. Diagnostics. 2023;13(3):335. [DOI:10.3390/diagnostics13030335]
22. Dong L, Duan X, Bin L, Wang J, Gao Q, Sun X, Xu Y. Evaluation of Fourier transform infrared (FTIR) spectroscopy with multivariate analysis as a novel diagnostic tool for lymph node metastasis in gastric cancer. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy. 2023;289:122209. [DOI:10.1016/j.saa.2022.122209]
23. Chu-xuan X, Fei J, Wei-tao S. Plasma markers for gastric cancer diagnosis: a metabolomics-and machine learning-based exploratory study. Chinese Journal of Public Health. 2023;39(2):1-6.
24. Muhammad JS, Manzoor S, Cui ZG, Khoder G. DNA Methylation-Mediated Overexpression of CXCL1 in Helicobacter pylori-Induced Gastric Cancer: In Silico-and In Vitro-Based Identification of a Potential Biomarker for Carcinogenesis. International Journal of Molecular Sciences. 2023;(1):795. [DOI:10.3390/ijms24010795]
25. Zheng P, Liu J. Cost-Effectiveness Analysis of Hp and New Gastric Cancer Screening Scoring System for Screening and Prevention of Gastric Cancer. Current Oncology. 2023;30(1):1132-45. [DOI:10.3390/curroncol30010086]
26. Wang SS, Guo ZP, Zhao XY. [Diagnostic Value of Serum Pepsinogen Ⅰ/Pepsinogen Ⅱ Combined with Tumor Markers for Helicobacter pylori-Positive Early-Stage Gastric Cancer]. Sichuan da xue xue bao Yi xue ban = Journal of Sichuan University Medical science edition. 2023;54(1):186-91.
27. Chen X, Liang D, Sun W, Shou X, Shang L, Shen X. Suspended bubble microcapsule delivery systems from droplet microfluidic technology for the local treatment of gastric cancer. Chemical Engineering Journal. 2023;458:141428. [DOI:10.1016/j.cej.2023.141428]
28. Ahn CR, Kim HI, Kim JE, Ha IJ, Ahn KS, Park J, Kim YW, Baek SH. Ponciri Fructus Immatarus Sensitizes the Apoptotic Effect of Hyperthermia Treatment in AGS Gastric Cancer Cells through ROS-Dependent HSP Suppression. Biomedicines. 2023;11(2):405. [DOI:10.3390/biomedicines11020405]
29. Carrasco N, Garrido M, Montenegro I, Madrid A, Hartley R, González I, Rubilar M, Villena J, Valenzuela-Valderrama M. Antitumoral Activity of Leptocarpha rivularis Flower Extracts against Gastric Cancer Cells. International Journal of Molecular Sciences. 2023;24(2):1439. [DOI:10.3390/ijms24021439]
30. Yu X, Peng W, Wang Y, Xu W, Chen W, Huang L, Xu H, He X, Wang S, Sun Q, Lu W. Palmitic Acid Inhibits the Growth and Metastasis of Gastric Cancer by Blocking the STAT3 Signaling Pathway. Cancers. 2023; 15(2):388. [DOI:10.3390/cancers15020388]
31. Li CS, Nguyen TV, Chai OH, Park BH, Lee JS, Kim SM. 3,3′-Diindolylmethane Augments 5-Fluorouracil-InducedGrowth Suppression in Gastric Cancer Cells through Suppression of the Akt/GSK-3β and WNT/Beta-Catenin. Journal of Oncology. 2023;2023:8268955. [DOI:10.1155/2023/8268955]
32. Poorshamohammad C, Liu L, Cheng X, Abbas Momtazi-Borojeni A, Chai J. Green synthesis of plant-stabilized Au nanoparticles for the treatment of gastric carcinoma. Arabian Journal of Chemistry. 2023;16(1):104386. [DOI:10.1016/j.arabjc.2022.104386]
33. Xu H, Shen X, Li X, Yang X, Chen C, Luo D. The natural product dehydrocurvularin induces apoptosis of gastric cancer cells by activating PARP-1 and caspase-3. Apoptosis. 2023;18:1-4. [DOI:10.1007/s10495-023-01811-x]
34. Zheng X, Song X, Shao Y, Xu B, Chen L, Zhou Q, Hu W, Zhang D, Wu C, Tao M, Zhu Y, Jiang J. Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: a meta-analysis. Oncotarget. 2017;8(34):57386-98. [DOI:10.18632/oncotarget.18065]
35. Zhang E, He X, Zhang C, Su J, Lu X, Si X, Chen J, Yin D, Han L, De W. A novel long noncoding RNA HOXC-AS3 mediates tumorigenesis of gastric cancer by binding to YBX1. Genome Biology. 2018;19(1):154. [DOI:10.1186/s13059-018-1523-0]
36. Pereira-Marques J, Ferreira RM, Pinto-Ribeiro I, Figueiredo C. Helicobacter pylori infection, the gastric microbiome and gastric cancer. Advances in Microbiology, Infectious Diseases and Public Health Volume. 2019; 11:195-210. [DOI:10.1007/5584_2019_366]
37. Gambardella V, Castillo J, Tarazona N, Gimeno-Valiente F, Martínez-Ciarpaglini C, Cabeza-Segura M, Roselló S, Roda D, Huerta M, Cervantes A, Fleitas T. The role of tumor-associated macrophages in gastric cancer development and their potential as a therapeutic target. Cancer Treatment Reviews. 2020;86:102015. [DOI:10.1016/j.ctrv.2020.102015]
38. Casamayor M, Morlock R, Maeda H, Ajani J.. Targeted literature review of the global burden of gastric cancer. Ecancermedicalscience. 2018;12:883. [DOI:10.3332/ecancer.2018.883]
39. Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, Dandona L, Fleming T, Forouzanfar MH, Hancock J, Hay RJ, Hunter-Merrill R, Huynh C, Hosgood HD, Johnson CO, Jonas JB, Khubchandani J, Kumar GA, Kutz M, Lan Q, Larson HJ, Liang X, Lim SS, Lopez AD, MacIntyre MF, Marczak L, Marquez N, Mokdad AH, Pinho C, Pourmalek F, Salomon JA, Sanabria JR, Sandar L, Sartorius B, Schwartz SM, Shackelford KA, Shibuya K, Stanaway J, Steiner C, Sun J, Takahashi K, Vollset SE, Vos T, Wagner JA, Wang H, Westerman R, Zeeb H, Zoeckler L, Abd-Allah F, Ahmed MB, Alabed S, Alam NK, Aldhahri SF, Alem G, Alemayohu MA, Ali R, Al-Raddadi R, Amare A, Amoako Y, Artaman A, Asayesh H, Atnafu N, Awasthi A, Saleem HB, Barac A, Bedi N, Bensenor I, Berhane A, Bernabé E, Betsu B, Binagwaho A, Boneya D, Campos-Nonato I, Castañeda-Orjuela C, Catalá-López F, Chiang P, Chibueze C, Chitheer A, Choi JY, Cowie B, Damtew S, das Neves J, Dey S, Dharmaratne S, Dhillon P, Ding E, Driscoll T, Ekwueme D, Endries AY, Farvid M, Farzadfar F, Fernandes J, Fischer F, TT GH, Gebru A, Gopalani S, Hailu A, Horino M, Horita N, Husseini A, Huybrechts I, Inoue M, Islami F, Jakovljevic M, James S, Javanbakht M, Jee SH, Kasaeian A, Kedir MS, Khader YS, Khang YH, Kim D, Leigh J, Linn S, Lunevicius R, El Razek HMA, Malekzadeh R, Malta DC, Marcenes W, Markos D, Melaku YA, Meles KG, Mendoza W, Mengiste DT, Meretoja TJ, Miller TR, Mohammad KA, Mohammadi A, Mohammed S, Moradi-Lakeh M, Nagel G, Nand D, Le Nguyen Q, Nolte S, Ogbo FA, Oladimeji KE, Oren E, Pa M, Park EK, Pereira DM, Plass D, Qorbani M, Radfar A, Rafay A, Rahman M, Rana SM, Søreide K, Satpathy M, Sawhney M, Sepanlou SG, Shaikh MA, She J, Shiue I, Shore HR, Shrime MG, So S, Soneji S, Stathopoulou V, Stroumpoulis K, Sufiyan MB, Sykes BL, Tabarés-Seisdedos R, Tadese F, Tedla BA, Tessema GA, Thakur JS, Tran BX, Ukwaja KN, Uzochukwu BSC, Vlassov VV, Weiderpass E, Wubshet Terefe M, Yebyo HG, Yimam HH, Yonemoto N, Younis MZ, Yu C, Zaidi Z, Zaki MES, Zenebe ZM, Murray CJL, Naghavi M. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncology. 2017;3(4):524-48. [DOI:10.1001/jamaoncol.2016.5688]
40. Machlowska J, Baj J, Sitarz M, Maciejewski R, Sitarz R. Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies. International Journal of Molecular Sciences. 2020;21(11):4012. [DOI:10.3390/ijms21114012]
41. Ilic M, Ilic I. Epidemiology of stomach cancer. World Journal of Gastroenterology. 2022;28(12):1187-203. [DOI:10.3748/wjg.v28.i12.1187]
42. Pernot S, Terme M, Radosevic-Robin N, Castan F, Badoual C, Marcheteau E, Penault-Llorca F, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Baptiste Bachet J, Borg C, Boige V, Voron T, Stanbury T, Tartour E, Gourgou S, Malka D, Taieb J. Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance. Gastric Cancer. 2020;23(1):73-81. [DOI:10.1007/s10120-019-00983-3]
43. Wang Q, Liu G, Hu C. Molecular classification of gastric adenocarcinoma. Gastroenterology Research. 2019; 12(6):275-82. [DOI:10.14740/gr1187]
44. Tang CT, Zeng L, Yang J, Zeng C, Chen Y. Analysis of the Incidence and Survival of Gastric Cancer Based on the Lauren Classification: A Large Population-Based Study Using SEER. Frontiers in Oncology. 2020;10:1212. [DOI:10.3389/fonc.2020.01212]
45. Wang XX, Ding Y, Wang SW, Dong D, Li HL, Chen J, Hu H, Lu C, Tian J, Shan XH. Intratumoral and peritumoral radiomics analysis for preoperative Lauren classification in gastric cancer. Cancer Imaging. 2020; 20(1):83. https://doi.org/10.1186/s40644-020-00358-3 [DOI:10.1186/s40644-023-00605-3]
46. Usui G, Matsusaka K, Mano Y, Urabe M, Funata S, Fukayama M, Ushiku T, Kaneda A. DNA Methylation and Genetic Aberrations in Gastric Cancer. Digestion. 2021;102(1):25-32. [DOI:10.1159/000511243]
47. Oue N, Sentani K, Sakamoto N, Uraoka N, Yasui W.. Molecular carcinogenesis of gastric cancer: Lauren classification, mucin phenotype expression, and cancer stem cells. International Journal of Clinical Oncology 2019; 24(7):771-8. [DOI:10.1007/s10147-019-01443-9]
48. Ramos MF, Pereira MA, Amorim LC, de Mello ES, Faraj SF, Ribeiro U, Hoff PM, Cecconello I, de Castria TB. Gastric cancer molecular classification and adjuvant therapy: Is there a different benefit according to the subtype? Journal of Surgical Oncology. 2020;121(5):804-13. [DOI:10.1002/jso.25792]
49. McLean MH, El-Omar EM. Genetics of gastric cancer. Nature Reviews Gastroenterology & Hepatology. 2014; 11(11):664-74. [DOI:10.1038/nrgastro.2014.143]
50. Slavin TP, Weitzel JN, Neuhausen SL, Schrader KA, Oliveira C, Karam R. Genetics of gastric cancer: what do we know about the genetic risks? Translational Gastroenterology and Hepatology. 2019;4:55. [DOI:10.21037/tgh.2019.07.02]
51. Shenoy S. CDH1 (E-Cadherin) Mutation and Gastric Cancer: Genetics, Molecular Mechanisms and Guidelines for Management. Cancer Management and Research. 2019;11:10477-86. [DOI:10.2147/CMAR.S208818]
52. Abdi E, Latifi‐Navid S, Zahri S, Yazdanbod A, Pourfarzi F. Risk factors predisposing to cardia gastric adenocarcinoma: Insights and new perspectives. Cancer Medicine. 2019;8(13):6114-26. [DOI:10.1002/cam4.2497]
53. Ebrahimi V, Soleimanian A, Ebrahimi T, Azargun R, Yazdani P, Eyvazi S, Tarhriz V. Epigenetic modifications in gastric cancer: Focus on DNA methylation. Gene. 2020;742:144577. [DOI:10.1016/j.gene.2020.144577]
54. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric Cancer: Descriptive Epidemiology, Risk Factors, Screening, and Prevention. Cancer Epidemiology, Biomarkers & Prevention. 2014;23(5):700-13. [DOI:10.1158/1055-9965.EPI-13-1057]
55. Arnold M, Park JY, Camargo MC, Lunet N, Forman D, Soerjomataram I. Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035. Gut. 2020;69(5):823-9. [DOI:10.1136/gutjnl-2019-320234]
56. Yan L, Chen Y, Chen F, Tao T, Hu Z, Wang J, You J, Wong BCY, Chen J, Ye W. Effect of Helicobacter pylori Eradication on Gastric Cancer Prevention: Updated Report From a Randomized Controlled Trial With 26.5 Years of Follow-up. Gastroenterology. 2022;163(1):154-62. [DOI:10.1053/j.gastro.2022.03.039]
57. Choi IJ, Kim CG, Lee JY, Kim Y-I, Kook MC, Park B, Joo J. Family history of gastric cancer and Helicobacter pylori treatment. New England Journal of Medicine. 2020;382(5):427-36. [DOI:10.1056/NEJMoa1909666]
58. Butt J, Varga MG, Wang T, Tsugane S, Shimazu T, Zheng W, Abnet CC, Yoo KY, Park SK, Kim J. Jee SH. Smoking, Helicobacter pylori serology, and gastric cancer risk in prospective studies from China, Japan, and Korea. Cancer Prevention Research. 2019;12(10):667-74. [DOI:10.1158/1940-6207.CAPR-19-0238]
59. Canale M, Casadei-Gardini A, Ulivi P, Arechederra M, Berasain C, Lollini P-L, Fernández-Barrena MG, Avila MA. Epigenetic mechanisms in gastric cancer: Potential new therapeutic opportunities. International Journal of Molecular Sciences. 2020;21(15):5500. [DOI:10.3390/ijms21155500]
60. Gullo I, Grillo F, Mastracci L, Vanoli A, Carneiro F, Saragoni L, Limarzi F, Ferro J, Parente P, Fassan M. Precancerous lesions of the stomach, gastric cancer and hereditary gastric cancer syndromes. Pathologica. 2020;112(3):166-85. [DOI:10.32074/1591-951X-166]
61. Poorolajal J, Moradi L, Mohammadi Y, Cheraghi Z, Gohari-Ensaf F. Risk factors for stomach cancer: a systematic review and meta-analysis. Epidemiology and Health. 2020;42:2020004. [DOI:10.4178/epih.e2020004]
62. Bai X, Ding SQ, Zhang XP, Han MH, Dai DQ. Exposure to Commonly Used Drugs and the Risk of Gastric Cancer: An Umbrella Review of Meta-Analyses. Cancers. 2023;15(2):372. [DOI:10.3390/cancers15020372]
63. Collatuzzo G, Pelucchi C, Negri E, López‐Carrillo L, Tsugane S, Hidaka A, Shigueaki Hamada G, Hernández‐Ramírez RU, López‐Cervantes M, Malekzadeh R. Porfarzi F. Exploring the interactions between Helicobacter pylori (Hp) infection and other risk factors of gastric cancer: A pooled analysis in the Stomach cancer Pooling (StoP) Project. International Journal of Cancer. 2021;149(6):1228-38. [DOI:10.1002/ijc.33678]
64. Miftahussurur M, Waskito LA, Syam AF, Nusi IA, Wibawa IDN, Rezkitha YAA, Siregar G, Yulizal O, Akil F, Uwan WB. Simanjuntak D. Analysis of risks of gastric cancer by gastric mucosa among Indonesian ethnic groups. PLoS ONE. 2019;14(5):e0216670. [DOI:10.1371/journal.pone.0216670]
65. Lam BQ, Srivastava R, Morvant J, Shankar S, Srivastava RK. Association of diabetes mellitus and alcohol abuse with cancer: Molecular mechanisms and clinical significance. Cancers. 2021;10(11):3077. [DOI:10.3390/cells10113077]
66. Wu B, Yang D, Yang S, Zhang G. Dietary salt intake and gastric cancer risk: a systematic review and meta-analysis. Frontiers in Nutrition. 2021;8:801228. [DOI:10.3389/fnut.2021.801228]
67. Murphy N, Jenab M, Gunter MJ. Adiposity and gastrointestinal cancers: epidemiology, mechanisms and future directions. Nature Reviews Gastroenterology & Hepatology. 2018;15(11):659-70. [DOI:10.1038/s41575-018-0038-1]
68. Yin J, Wu X, Li S, Li C, Guo Z. Impact of environmental factors on gastric cancer: A review of the scientific evidence, human prevention and adaptation. Journal of Environmental Sciences. 2020;89:65-79. [DOI:10.1016/j.jes.2019.09.025]
69. Guo Y, Cao XS, Zhou MG, Yu B. Gastric microbiota in gastric cancer: Different roles of Helicobacter pylori and other microbes. Frontier in Cellular and Infection Microbiology. 2023;12:1975. [DOI:10.3389/fcimb.2022.1105811]
70. Shah D, Bentrem D. Environmental and genetic risk factors for gastric cancer. Journal of Surgical Oncology. 2022;125(7):1096-103. [DOI:10.1002/jso.26869]
71. Lin Y, Docherty SL, Porter LS, Bailey DE. Symptom experience and self-management for multiple co-occurring symptoms in patients with gastric cancer: A qualitative study. European Journal of Oncology Nursing. 2020;49:101860. [DOI:10.1016/j.ejon.2020.101860]
72. Yu J, Jung J, Park SR, Ryu MH, Park Jh, Kim JH, Yoon SM. Role of palliative radiotherapy in bleeding control in patients with unresectable advanced gastric cancer. BMC Cancer. 2021;21(1):413. [DOI:10.1186/s12885-021-08145-4]
73. Majewski M, Mertowska P, Mertowski S, Smolak K, Grywalska E, Torres K. Microbiota and the Immune System; Actors in the Gastric Cancer Story. Cancers. 2022;14(15):3832. [DOI:10.3390/cancers14153832]
74. Dalhammar K, Kristensson J, Falkenback D, Rasmussen BH, Malmström M. Symptoms, problems and quality of life in patients newly diagnosed with oesophageal and gastric cancer - a comparative study of treatment strategy. BMC Cancer. 2022;22(1):434. [DOI:10.1186/s12885-022-09536-x]
75. Lin Y. Common and co-occurring symptoms experienced by patients with gastric cancer. Oncology Nursing Society. 2020;47(2):187-202. [DOI:10.1188/20.ONF.187-202]
76. Wang FH, Shen L, Li J, Zhou ZW, Liang H, Zhang XT, Tang L, Xin Y, Jin J, Zhang YJ, Yuan XL, Liu TS, Li GX, Wu Q, Xu HM, Ji JF, Li YF, Wang X, Yu S, Liu H, Guan WL, Xu RH. The Chinese Society of Clinical Oncology (CSCO): clinical guidelines for the diagnosis and treatment of gastric cancer. Cancer Communications. 2019;39(1):10. [DOI:10.1186/s40880-019-0349-9]
77. Wang FH, Zhang XT, Li YF, Tang L, Qu XJ, Ying JE, Zhang J, Sun LY, Lin RB, Qiu H. Wang C. The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021. Cancer Communications. 2021;41(8):747-95. [DOI:10.1002/cac2.12193]
78. Wu D, Zhang P, Ma J, Xu J, Yang L, Xu W, Que H, Chen M, Xu H. Serum biomarker panels for the diagnosis of gastric cancer. Cancer Medicine. 2019;8(4):1576-83. [DOI:10.1002/cam4.2055]
79. Niu PH, Zhao LL, Wu HL, Zhao DB, Chen YT. Artificial intelligence in gastric cancer: Application and future perspectives. World Journal of Gastroenterology. 2020;26(36):5408-19. [DOI:10.3748/wjg.v26.i36.5408]
80. Zhu Y, Wang QC, Xu MD, Zhang Z, Cheng J, Zhong YS, Zhang YQ, Chen WF, Yao LQ, Zhou PH, Li QL. Application of convolutional neural network in the diagnosis of the invasion depth of gastric cancer based on conventional endoscopy. Gastrointestinal Endoscopy. 2019;89(4):806-15.e1. [DOI:10.1016/j.gie.2018.11.011]
81. Ueyama H, Kato Y, Akazawa Y, Yatagai N, Komori H, Takeda T, Matsumoto K, Ueda K, Matsumoto K, Hojo M. Yao T. Application of artificial intelligence using a convolutional neural network for diagnosis of early gastric cancer based on magnifying endoscopy with narrow‐band imaging. Journal of Gastroenterology and Hepatology. 2021;36(2):482-9. [DOI:10.1111/jgh.15190]
82. Horiuchi Y, Hirasawa T, Ishizuka N, Tokai Y, Namikawa K, Yoshimizu S, Ishiyama A, Yoshio T, Tsuchida T, Fujisaki J, Tada T. Performance of a computer-aided diagnosis system in diagnosing early gastric cancer using magnifying endoscopy videos with narrow-band imaging (with videos). Gastrointestinal Endoscopy. 2020;92(4):856-65.e1. [DOI:10.1016/j.gie.2020.04.079]
83. Cai J, Chen Z, Zuo X. circSMARCA5 Functions as a Diagnostic and Prognostic Biomarker for Gastric Cancer. Disease markers. 2019;2019:2473652. https://doi.org/10.1155/2019/2473652 [DOI:10.1155/2019/9356804]
84. Ma Y, Xu H, Zhou Z, Tian Y, Du K, Zhang H, Jiang X, Lu J, Niu Y, Tu L, Liu H, Zhu H, Chen P, Liu Y. CFNC, a neocryptolepine derivative, inhibited the growth of gastric cancer AGS cells by inhibiting PI3K/AKT signaling pathway. European Journal of Pharmacology. 2023;938:175408. [DOI:10.1016/j.ejphar.2022.175408]
85. Sexton RE, Al Hallak MN, Diab M, Azmi AS. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer and Metastasis Reviews. 2020;39(4):1179-203. [DOI:10.1007/s10555-020-09925-3]
86. Jiang H, Shi Z, Wang P, Wang C, Yang L, Du G, Zhang H, Shi B, Jia J, Li Q, Wang H, Li Z. Claudin18.2-Specific Chimeric Antigen Receptor Engineered T Cells for the Treatment of Gastric Cancer. JNCI: Journal of the National Cancer Institute. 2018;111(4):409-18. [DOI:10.1093/jnci/djy134]
87. Gao Q, Cui L, Huang C, Chen Z, Wang X, Wen S, Zhao Y, Wang M, Shen B, Zhu W. Gastric cancer-derived mesenchymal stem cells promote gastric cancer cell lines migration by modulating CD276 expression. Experimental Cell Research. 2023;422(1):113414. [DOI:10.1016/j.yexcr.2022.113414]
88. Zali H, Rezaei-Tavirani M, Azodi M. Gastric cancer: prevention, risk factors and treatment. Gastroenterology and Hepatology from Bed to Bench. 2011;4(4):175-85.
89. Park JY, von Karsa L, Herrero R. Prevention strategies for gastric cancer: a global perspective. Clinical Endoscopy. 2014;47(6):478-89. [DOI:10.5946/ce.2014.47.6.478]
90. Cheng XJ, Lin JC, Tu SP. Etiology and Prevention of Gastric Cancer. Gastrointestinal Tumors. 2016;3(1):25-36. [DOI:10.1159/000443995]
91. Sitarz R, Skierucha M, Mielko J, Offerhaus GJA, Maciejewski R, Polkowski WP. Gastric cancer: epidemiology, prevention, classification, and treatment. Cancer Management and Research. 2018;10:239. [DOI:10.2147/CMAR.S149619]
92. Cuzzuol BR, Vieira ES, Araújo GRL, Apolonio JS, de Carvalho LS, da Silva Junior RT, de Brito BB, de Melo FF. Gastric cancer: a brief review, from risk factors to treatment. Archives of Gastroenterology Research. 2020;1(2):34-9.
93. Yan L, Chen Y, Chen F, Tao T, Hu Z, Wang J, You J, Wong BC, Chen J, Ye W. Effect of Helicobacter pylori eradication on gastric cancer prevention: updated report from a randomized controlled trial with 26.5 years of follow-up. Gastroenterology. 2022;163(1):154-62. 3. [DOI:10.1053/j.gastro.2022.03.039]
94. Kim J, Oh A, Truong H, Laszkowska M, Camargo MC, Abrams J, Hur C. Low sodium diet for gastric cancer prevention in the United States: Results of a Markov model. Cancer Medicine. 2021;10(2):684-92. [DOI:10.1002/cam4.3615]
95. Qu YM, Chen A, Zhao X, Wang Z, Guo D, Shao SL, Tao YY, Li QJ, Wang MY, Ma WS. Huntingtin-associated protein 1 is a potential tumor suppressor for gastric cancer. Molecular Biology Reports. 2023;50(2):1517-31. [DOI:10.1007/s11033-022-08090-w]
96. Gunathilake MN, Lee J, Choi IJ, Kim Y-I, Ahn Y, Park C, Kim J. Association between the relative abundance of gastric microbiota and the risk of gastric cancer: a case-control study. Scientific Reports. 2019;9(1):1-11. [DOI:10.1038/s41598-019-50054-x]
97. Ogunrinola GA, Oyewale JO, Oshamika OO, Olasehinde GI. The Human Microbiome and Its Impacts on Health. International Journal of Microbiology. 2020;2020:8045646. [DOI:10.1155/2020/8045646]
98. Zhang S, Shi D, Li M, Li Y, Wang X, Li W. The relationship between gastric microbiota and gastric disease. Scandinavian Journal of Gastroenterology. 2019;54(4):391-6. [DOI:10.1080/00365521.2019.1591499]
99. Conti L, Annibale B, Lahner E. Autoimmune Gastritis and Gastric Microbiota. Microorganisms. 2020;8(11):1827. [DOI:10.3390/microorganisms8111827]
100. Koga Y. Microbiota in the stomach and application of probiotics to gastroduodenal diseases. World Journal of Gastroenterology. 2022;28(47):6702-15. [DOI:10.3748/wjg.v28.i47.6702]
101. Wen J, Lau HCH, Peppelenbosch M, Yu J. Gastric Microbiota beyond H. pylori: An Emerging Critical Character in Gastric Carcinogenesis. Biomedicines. 2021;9(11):1680. [DOI:10.3390/biomedicines9111680]
102. Stewart OA, Wu F, Chen Y. The role of gastric microbiota in gastric cancer. Gut Microbes. 2020;11(5):1220-30. [DOI:10.1080/19490976.2020.1762520]
103. Whisner CM, Athena Aktipis C. The Role of the Microbiome in Cancer Initiation and Progression: How Microbes and Cancer Cells Utilize Excess Energy and Promote One Another's Growth. Current Nutrition Reports. 2019;8(1):42-51. [DOI:10.1007/s13668-019-0257-2]
104. Meng C, Bai C, Brown TD, Hood LE, Tian Q. Human Gut Microbiota and Gastrointestinal Cancer. Genomics, Proteomics & Bioinformatics. 2018;16(1):33-49. [DOI:10.1016/j.gpb.2017.06.002]
105. Liu X, Shao L, Liu X, Ji F, Mei Y, Cheng Y, Liu F, Yan C, Li L, Ling Z. Alterations of gastric mucosal microbiota across different stomach microhabitats in a cohort of 276 patients with gastric cancer. EBioMedicine. 2019;40:336-48. [DOI:10.1016/j.ebiom.2018.12.034]
106. Alipour M. Molecular Mechanism of Helicobacter pylori-Induced Gastric Cancer. Journal of Gastrointestinal Cancer. 2021;52(1):23-30. [DOI:10.1007/s12029-020-00518-5]
107. Baj J, Korona-Głowniak I, Forma A, Maani A, Sitarz E, Rahnama-Hezavah M, Radzikowska E, Portincasa P. Mechanisms of the Epithelial-Mesenchymal Transition and Tumor Microenvironment in Helicobacter pylori-Induced Gastric Cancer. 2020;9(4):1055. [DOI:10.3390/cells9041055]
108. Dong Z, Chen B, Pan H, Wang D, Liu M, Yang Y, Zou M, Yang J, Xiao K, Zhao R, Zheng X, Zhang L, Zhang Y. Detection of Microbial 16S rRNA Gene in the Serum of Patients With Gastric Cancer. Frontiers in Oncology. 2019;9:608. [DOI:10.3389/fonc.2019.00608]
109. Yang L, Li A, Wang Y, Zhang Y. Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy. Signal Transduction and Targeted Therapy. 2023;8(1):35. [DOI:10.1038/s41392-022-01304-4]
110. Wang M, Yang G, Tian Y, Zhang Q, Liu Z, Xin Y. The role of the gut microbiota in gastric cancer: the immunoregulation and immunotherapy. Frontiers in Immunology. 2023;14:1183331. [DOI:10.3389/fimmu.2023.1183331]
111. Liu W, Zhang Q, Zhang Y, Sun L, Xiao H, Luo B. Epstein-Barr Virus Regulates Endothelin-1 Expression through the ERK/FOXO1 Pathway in EBV-Associated Gastric Cancer. Microbiology Spectrum. 2023;11(1):00898-22. [DOI:10.1128/spectrum.00898-22]
112. Xu S, Xiang C, Wu J, Teng Y, Wu Z, Wang R, Lu B, Zhan Z, Wu H, Zhang J. Tongue Coating Bacteria as a Potential Stable Biomarker for Gastric Cancer Independent of Lifestyle. Digestive Diseases and Sciences. 2021;66(9):2964-80. [DOI:10.1007/s10620-020-06637-0]
113. Park JY, Kang CS, Seo HC, Shin JC, Kym SM, Park YS, Shin TS, Kim JG, Kim YK. Bacteria-Derived Extracellular Vesicles in Urine as a Novel Biomarker for Gastric Cancer: Integration of Liquid Biopsy and Metagenome Analysis. Cancers. 2021;13(18):4687. [DOI:10.3390/cancers13184687]
114. Wu J, Zhang C, Xu S, Xiang C, Wang R, Yang D, Lu B, Shi L, Tong R, Teng Y, Dong W, Zhang J. Fecal Microbiome Alteration May Be a Potential Marker for Gastric Cancer. Disease Markers. 2020;2020:3461315. [DOI:10.1155/2020/3461315]
115. Yu D, Yang J, Jin M, Zhou B, Shi L, Zhao L, Zhang J, Lin Z, Ren J, Liu L, Zhang T, Liu H. Fecal Streptococcus Alteration Is Associated with Gastric Cancer Occurrence and Liver Metastasis. MBio 2021;12(6):02994-21. [DOI:10.1128/mBio.02994-21]
116. Zhang C, Hu A, Li J, Zhang F, Zhong P, Li Y, Li Y. Combined Non-Invasive Prediction and New Biomarkers of Oral and Fecal Microbiota in Patients With Gastric and Colorectal Cancer. Frontiers in Cellular and Infection Microbiology. 2022;12:830648. [DOI:10.3389/fcimb.2022.830684]
117. Hu YL, Pang W, Huang Y, Zhang Y, Zhang CJ. The Gastric Microbiome Is Perturbed in Advanced Gastric Adenocarcinoma Identified Through Shotgun Metagenomics. Frontiers in Cellular and Infection Microbiology. 2018;8:433. [DOI:10.3389/fcimb.2018.00433]
118. Chen WD, Zhang X, Zhang MJ, Zhang YP, Shang ZQ, Xin YW, Zhang Y. Salivary Fusobacterium nucleatum serves as a potential diagnostic biomarker for gastric cancer. World Journal of Gastroenterology. 2022;28(30):4120-32. [DOI:10.3748/wjg.v28.i30.4120]
119. Song L, Song M, Camargo MC, Van Duine J, Williams S, Chung Y, Kim KM, Lissowska J, Sivins A, Gao W, Karthikeyan K, Park J, Leja M, Cohen JI, LaBaer J, Qiu J, Rabkin CS. Identification of anti-Epstein-Barr virus (EBV) antibody signature in EBV-associated gastric carcinoma. Gastric Cancer. 2021;24(4):858-67. [DOI:10.1007/s10120-021-01170-z]
120. Rommasi F. Bacterial-Based Methods for Cancer Treatment: What We Know and Where We Are. Oncology and Therapy. 2022;10(1):23-54. [DOI:10.1007/s40487-021-00177-x]
121. Yang J, Zhou X, Liu X, Ling Z, Ji F. Role of the Gastric Microbiome in Gastric Cancer: From Carcinogenesis to Treatment. Frontiers in Microbiology. 2021;12:641322. [DOI:10.3389/fmicb.2021.641322]
122. Song S, Vuai MS, Zhong M. The role of bacteria in cancer therapy - enemies in the past, but allies at present. Infectious Agents and Cancer. 2018;13(1):9. [DOI:10.1186/s13027-018-0180-y]
123. Baindara P, Mandal SM. Bacteria and bacterial anticancer agents as a promising alternative for cancer therapeutics. Biochimie. 2020;177:164-89. [DOI:10.1016/j.biochi.2020.07.020]
124. Duan X, Chen P, Xu X, Han M, Li J. Role of Gastric Microorganisms Other than Helicobacter pylori in the Development and Treatment of Gastric Diseases. BioMed Research International. 2022;2022:6263423. [DOI:10.1155/2022/6263423]
125. Yarmohammadi M, Yadegar A, Ebrahimi MT, Zali MR. Effects of a Potential Probiotic Strain Lactobacillus gasseri ATCC 33323 on Helicobacter pylori-Induced Inflammatory Response and Gene Expression in Coinfected Gastric Epithelial Cells. Probiotics and Antimicrobial Proteins. 2021;13(3):751-64. [DOI:10.1007/s12602-020-09721-z]
126. Takeda S, Igoshi K, Tsend-Ayush C, Oyunsuren T, Sakata R, Koga Y, Arima Y, Takeshita M. Lactobacillus paracasei strain 06TCa19 suppresses inflammatory chemokine induced by Helicobacter pylori in human gastric epithelial cells. Human Cell. 2017;30(4):258-66. [DOI:10.1007/s13577-017-0172-z]
127. Shen S, Ren F, Qin H, Bukhari I, Yang J, Gao D, Ouwehand AC, Lehtinen MJ, Zheng P, Mi Y. Lactobacillus acidophilus NCFM and Lactiplantibacillus plantarum Lp-115 inhibit Helicobacter pylori colonization and gastric inflammation in a murine model. Frontiers in Cellular and Infection Microbiology. 2023;13:196084. [DOI:10.3389/fcimb.2023.1196084]
128. Rasouli BS, Ghadimi-Darsajini A, Nekouian R, Iragian GR. In vitro activity of probiotic Lactobacillus reuteri against gastric cancer progression by downregulation of urokinase plasminogen activator/urokinase plasminogen activator receptor gene expression. Journal of Cancer Research and Therapeutics. 2017;13(2):246-51. [DOI:10.4103/0973-1482.204897]
129. Pakbin B, Pishkhan Dibazar S, Allahyari S, Javadi M, Farasat A, Darzi S. Probiotic Saccharomyces cerevisiae var. boulardii supernatant inhibits survivin gene expression and induces apoptosis in human gastric cancer cells. Food Science & Nutrition. 2021;9(2):692-700. [DOI:10.1002/fsn3.2032]
130. Maleki-Kakelar H, Dehghani J, Barzegari A, Barar J, Shirmohamadi M, Sadeghi J, Omidi Y. Lactobacillus plantarum induces apoptosis in gastric cancer cells via modulation of signaling pathways in Helicobacter pylori. BioImpacts: BI. 2020;10(2):65-72. [DOI:10.34172/bi.2020.09]
131. Pan ST, Li ZL, He ZX, Qiu JX, Zhou SF. Molecular mechanisms for tumour resistance to chemotherapy. Clinical and Experimental Pharmacology and Physiology. 2016;43(8):723-37. [DOI:10.1111/1440-1681.12581]
132. Amjad MT, Chidharla A, Kasi A. Cancer Chemotherapy. In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2022, PMID: 33232037.
133. Tegels JJ, De Maat MF, Hulsewé KW, Hoofwijk AG, Stoot JH. Improving the outcomes in gastric cancer surgery. World Journal of Gastroenterology. 2014;20(38):13692-704. [DOI:10.3748/wjg.v20.i38.13692]
134. Majeed H, Gupta V. Adverse Effects Of Radiation Therapy. In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2022, PMID: 33085406.
135. Ding B, Lou W, Xu L, Li R, Fan W. Analysis the prognostic values of solute carrier (SLC) family 39 genes in gastric cancer. American Journal of Translational Research. 2019;11(1):486-98.
136. Li Y, Zheng D, Wang F, Xu Y, Yu H, Zhang H. Expression of Demethylase Genes, FTO and ALKBH1, Is Associated with Prognosis of Gastric Cancer. Digestive Diseases and Sciences. 2019;64(6):1503-13. [DOI:10.1007/s10620-018-5452-2]
137. Hao S, Lv J, Yang Q, Wang A, Li Z, Guo Y, Zhang G. Identification of Key Genes and Circular RNAs in Human Gastric Cancer. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2019;25:2488-504. [DOI:10.12659/MSM.915382]
138. Basati G, Mohammadpour H, Emami Razavi A. Association of High Expression Levels of SOX2, NANOG, and OCT4 in Gastric Cancer Tumor Tissues with Progression and Poor Prognosis. Journal of Gastrointestinal Cancer. 2020;51(1):41-7. [DOI:10.1007/s12029-018-00200-x]
139. Cai H, Jing C, Chang X, Ding D, Han T, Yang J, Lu Z, Hu X, Liu Z, Wang J, Shang L, Wu S, Meng P, Lin L, Zhao J, Nie M, Yin K. Mutational landscape of gastric cancer and clinical application of genomic profiling based on target next-generation sequencing. Journal of Translational Medicine. 2019;17(1):189. [DOI:10.1186/s12967-019-1941-0]
140. Chong X, Peng R, Sun Y, Zhang L, Zhang Z. Identification of key genes in gastric cancer by bioinformatics analysis. BioMed Research International. 2020;2020:7658230. [DOI:10.1155/2020/7658230]
141. Liu M, Yao B, Gui T, Guo C, Wu X, Li J, Ma L, Deng Y, Xu P, Wang Y, Yang D, Li Q, Zeng X, Li X, Hu R, Ge J, Yu Z, Chen Y, Chen B, Ju J, Zhao Q. PRMT5-dependent transcriptional repression of c-Myc target genes promotes gastric cancer progression. Theranostics. 2020;10(10):4437-52. [DOI:10.7150/thno.42047]
142. Janjigian YY, Shitara K, Moehler MH, Garrido M, Gallardo C, Shen L, Yamaguchi K, Wyrwicz L, Skoczylas T, Bragagnoli ASC, Liu T, Tehfe M, Elimova E, Maya REB, Cleary JM, Karamouzis M, Soleymani S, Lei M, Amaya-Chanaga C, Ajani JA. Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 3-year follow-up from CheckMate 649. Journal of Clinical Oncology. 2023;41(16):4025-4025. [DOI:10.1200/JCO.2023.41.16_suppl.4025]
143. Chung HC, Bang Y-J, S Fuchs C, Qin S-K, Satoh T, Shitara K, Tabernero J, Van Cutsem E, Alsina M, Cao ZA, Lu J. First-line pembrolizumab/placebo plus trastuzumab and chemotherapy in HER2-positive advanced gastric cancer: KEYNOTE-811. Future Oncology. 2021;17(5):491-501. [DOI:10.2217/fon-2020-0737]
144. Chen W, Shi K, Liu J, Yang P, Han R, Pan M, Yuan L, Fang C, Yu Y, Qian Z. Sustained co-delivery of 5-fluorouracil and cis-platinum via biodegradable thermo-sensitive hydrogel for intraoperative synergistic combination chemotherapy of gastric cancer. Bioactive Materials. 2023;23:1-15. https://doi.org/10.1016/j.bioactmat.2022.10.004 [DOI:10.1016/j.bioactmat.2022.07.023]
145. Lee Ck, Rha SY, Kim HS, Jung M, Kang B, Che J, Kwon WS, Park S, Bae WK, Koo DH, Shin SJ, Kim H, Jeung HC, Zang DY, Lee SK, Nam CM, Chung HC. A single arm phase Ib/II trial of first-line pembrolizumab, trastuzumab and chemotherapy for advanced HER2-positive gastric cancer. Nature Communications. 2022;13(1):6002. [DOI:10.1038/s41467-022-33267-z]
146. He L, Chen H, Qi Q, Wu N, Wang Y, Chen M, Feng Q, Dong B, Jin R, Jiang L. Schisandrin B suppresses gastric cancer cell growth and enhances the efficacy of chemotherapy drug 5-FU in vitro and in vivo. European Journal of Pharmacology. 2022;920:174823. [DOI:10.1016/j.ejphar.2022.174823]
147. Shitara K, Bang YJ, Iwasa S, Sugimoto N, Ryu M-H, Sakai D, Chung HC, Kawakami H, Yabusaki H, Lee J. Saito K. Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. New England Journal of Medicine. 2020;382(25):2419-30. [DOI:10.1056/NEJMoa2004413]
148. Muro K, Bang YJ, Shankaran V, Geva R, Catenacci DVT, Gupta S, Eder JP, Berger R, Gonzalez EJ, Ray A, Dolled-Filhart M, Emancipator K, Pathiraja K, Lunceford JK, Cheng JD, Koshiji M, Chung HC. Relationship between PD-L1 expression and clinical outcomes in patients (Pts) with advanced gastric cancer treated with the anti-PD-1 monoclonal antibody pembrolizumab (Pembro; MK-3475) in KEYNOTE-012. Journal of Clinical Oncology. 2015;33(3):3-3 [DOI:10.1200/jco.2015.33.3_suppl.3]
149. Bang YJ, Kang YK, Catenacci DV, Muro K, Fuchs CS, Geva R, Hara H, Golan T, Garrido M, Jalal SI, Borg C, Doi T, Yoon HH, Savage MJ, Wang J, Dalal RP, Shah S, Wainberg ZA, Chung HC. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Gastric Cancer. 2019;22(4):828-37. [DOI:10.1007/s10120-018-00909-5]
150. Deng L, Zhao L, Liu L, Huang H. Systemic investigation of inetetamab in combination with small molecules to treat HER2-overexpressing breast and gastric cancers. Open Life Sciences. 2023;18(1):20220535. [DOI:10.1515/biol-2022-0535]
151. Mezynski MJ, Farrelly AM, Cremona M, Carr A, Morgan C, Workman J, Armstrong P, McAuley J, Madden S, Fay J, Sheehan KM, Kay EW, Holohan C, Elamin Y, Rafee S, Morris PG, Breathnach O, Grogan L, Hennessy BT, Toomey S. Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer. Journal of Translational Medicine. 2021;19(1):184. [DOI:10.1186/s12967-021-02842-1]
152. Shin SH, Park SS, Ju EJ, Park J, Ko EJ, Hwang JJ, Suh YA, Jang SJ, Lee JS, Ko BK. Kim KT. Establishment of a patient-derived xenograft for development of personalized HER2-targeting therapy in gastric cancer. Anticancer Research. 2018;38(1):287-93. [DOI:10.21873/anticanres.12220]
153. Guo Y, Zhang Y, Gerhard M, Gao JJ, Mejias-Luque R, Zhang L, Vieth M, Ma JL, Bajbouj M, Suchanek S, Liu WD, Ulm K, Quante M, Li ZX, Zhou T, Schmid R, Classen M, Li WQ, You WC, Pan KF. Effect of Helicobacter pylori on gastrointestinal microbiota: a population-based study in Linqu, a high-risk area of gastric cancer. Gut. 2020;69(9):1598. [DOI:10.1136/gutjnl-2019-319696]
154. Chiang TH, Chang WJ, Chen SLS, Yen AMF, Fann JCY, Chiu SYH, Chen YR, Chuang SL, Shieh CF, Liu CY, Chiu HM, Chiang H, Shun CT, Lin MW, Wu MS, Lin JT, Chan CC, Graham DY, Chen HH, Lee YC. Mass eradication of Helicobacter pylori to reduce gastric cancer incidence and mortality: a long-term cohort study on Matsu Islands. Gut. 2021;70(2):243. [DOI:10.1136/gutjnl-2020-322200]
155. Huang W, Wen F, Ruan S, Gu P, Gu S, Song S, Zhou J, Li Y, Liu J, Shu P. Integrating HPLC-Q-TOF-MS/MS, network pharmacology and experimental validation to decipher the chemical substances and mechanism of modified Gui-shao-liu-jun-zi decoction against gastric cancer. Journal of Traditional and Complementary Medicine. 2023;13(3):245-262. [DOI:10.1016/j.jtcme.2023.01.002]
156. Daniyal M, Liu Y, Yang Y, Xiao F, Fan J, Yu H, Qiu Y, Liu B, Wang W, Yuhui Q. Anti‐gastric cancer activity and mechanism of natural compound "Heilaohulignan C" isolated from kadsura coccinea. 2021;35(7):3977-87. [DOI:10.1002/ptr.7114]
157. Zhong L, Yang B, Zhang Z, Wang J, Wang X, Guo Y, Huang W, Wang Q, Cai G, Xia F, Zhou S, Ma S, Nie Y, Lei J, Li M, Liu P, Deng W, Liu Y, Han F, Wang J. Targeting autophagy peptidase ATG4B with a novel natural product inhibitor Azalomycin F4a for advanced gastric cancer. Cell Death & Disease. 2022;13(2):161. [DOI:10.1038/s41419-022-04608-z]
158. Wang H, Luo Y, Hu Y, Feng X, Feng J, Chu Z, Ou S, Dai X, Wang X, Liu Y. Triptonoterpene, a Natural Product from Celastrus orbiculatus Thunb, Has Biological Activity against the Metastasis of Gastric Cancer Cells. Molecules. 2022;27(22):8005. [DOI:10.3390/molecules27228005]
159. Peng X, Shi J, Zhao Z, Tong R, Zhang X, Zhong L. Emetine, a small molecule natural product, displays potent anti-gastric cancer activity via regulation of multiple signaling pathways. Cancer Chemotherapy and Pharmacology. 2023;91(4):303-15. [DOI:10.1007/s00280-023-04521-y]
160. Dai D, Yang Y, Yu J, Dang T, Qin W, Teng L, Ye J, Jiang H. Interactions between gastric microbiota and metabolites in gastric cancer. Cell Death & Disease. 2021;12(12):1104. [DOI:10.1038/s41419-021-04396-y]
161. Hsieh YY, Tung SY, Pan HY, Yen CW, Xu HW, Lin YJ, Deng YF, Hsu WT, Wu CS, Li C. Increased abundance of Clostridium and Fusobacterium in gastric microbiota of patients with gastric cancer in Taiwan. Scientific Reports. 2018;8(1):1-11. [DOI:10.1038/s41598-017-18596-0]
162. Li TH, Qin Y, Sham PC, Lau KS, Chu KM, Leung WK. Alterations in Gastric Microbiota After H. Pylori Eradication and in Different Histological Stages of Gastric Carcinogenesis. Scientific Reports. 2017;7(1):44935. [DOI:10.1038/srep44935]
163. Chen XH, Wang A, Chu AN, Gong YH, Yuan Y. Mucosa-Associated Microbiota in Gastric Cancer Tissues Compared With Non-cancer Tissues.Frontiers in Microbiology. 2019;10:1261. [DOI:10.3389/fmicb.2019.01261]
164. Qi Yf, Sun Jn, Ren Lf, Cao Xl, Dong Jh, Tao K, Guan Xm, Cui Yn, Su W. Intestinal Microbiota Is Altered in Patients with Gastric Cancer from Shanxi Province, China. Digestive Diseases and Sciences. 2019;64(5):1193-203. [DOI:10.1007/s10620-018-5411-y]
165. Hansen A, Johannesen TB, Spiegelhauer M, Kupcinskas J, Urba M, Skieceviciene J, Jonaitis L, Frandsen T, Kupcinskas L, Fuursted K. Andersen LP. Distinct composition and distribution of the gastric mycobiota observed between dyspeptic and gastric cancer patients evaluated from gastric biopsies. Microbial Health Dis. 2020;2:340.
166. Wang Z, Gao X, Zeng R, Wu Q, Sun H, Wu W, Zhang X, Sun G, Yan B, Wu L, Ren R, Guo M, Peng L, Yang Y. Changes of the Gastric Mucosal Microbiome Associated With Histological Stages of Gastric Carcinogenesis. Frontiers in Microbiology. 2020;11:997. [DOI:10.3389/fmicb.2020.00997]

Add your comments about this article : Your username or Email:

Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2024 All Rights Reserved | Iranian Journal of Blood and Cancer

Designed & Developed by : Yektaweb